nach oben

09.05.2024 | Original Contribution

Iron absorption in adults with sickle cell anemia: a stable-isotope approach

verfasst von: Juliana Omena¹, Flávia Fioruci Bezerra¹, Vanessa Monteiro Voll¹, Bernardo Ferreira Braz, Ricardo Erthal Santelli, Carmen Marino Donangelo, Gustavo Federico Jauregui, Andrea Soares Ribeiro, Cláudia dos Santos Cople Rodrigues, Marta Citelli

Erschienen in: European Journal of Nutrition

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Iron absorption in sickle cell anemia (SCA) remains unclear and studies in adults with SCA are scarce. The aim of this study was to evaluate the iron absorption SCA adults and its association with iron status and hepcidin concentration.

Methods

SCA patients (n = 13; SCA_total) and control participants (n = 10) ingested an oral stable iron isotope (⁵⁷Fe). Iron absorption was measured by inductively coupled plasma mass spectrometry (ICP-MS) 14 days after isotope administration. Patients with ≥ 1000 ng/mL serum ferritin were considered to present iron overload (IO) (SCAio+; n = 3) and others classified without IO (SCAio-; n = 10).

Results

Iron absorption in the control group ranged from 0.3 to 26.5% (median = 0.9%), while it varied from 0.3 to 5.4% in SCAio+ (median = 0.5%) and from 0.3 to 64.2% in the SCAio- (median = 6.9%). Hepcidin median values were 14.1 ng/mL (3.0–31.9 ng/mL) in SCAio-, 6.2 ng/mL (3.3–7.8 ng/mL) in SCAio + and 6.2 ng/mL (0.6–9.3 ng/mL) in control. Iron absorption was associated with ferritin level (r = − 0.641; p = 0.018) and liver iron concentration (LIC; r = − 0.786; p = 0.036) in the SCA_total group.

Conclusion

Our data suggest that SCAio- individuals may be at risk of developing primary IO. Simultaneously, secondary IO may induce physiological adaptation, resulting in reduced iron absorption. Further studies evaluating intestinal iron absorption using larger sample sizes should be conducted to help establish a safe nutrition approach to be adopted and to ensure the security of food-fortifying public policies for these patients.

Trial registration

This trial was registered at www.ensaiosclinicos.gov.br (Identifier RBR-4b7v8pt).

Conran N, Franco-Penteado CF, Costa FF (2009) Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 33(1):1–16. https://doi.org/10.1080/03630260802625709CrossRefPubMed

Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376(9757):2018–2031. https://doi.org/10.1016/S0140-6736(10)61029-XCrossRefPubMed

Modell B, Darlinson M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86(6):480–487. https://doi.org/10.2471/blt.06.036673CrossRefPubMedPubMedCentral

Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L et al (2018) Sickle cell disease. Nat Rev Dis Primers 4:18010. https://doi.org/10.1038/nrdp.2018.10CrossRefPubMed

Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T et al (2000) Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 96(1):76–79. https://doi.org/10.1182/blood.V96.1.76CrossRefPubMed

Josephson CD, Su LL, Hillyer KL, Hillyer CD (2007) Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 21(2):118–133. https://doi.org/10.1016/j.tmrv.2006.11.003CrossRefPubMed

Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C et al (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339(1):5–11. https://doi.org/10.1056/NEJM199807023390102CrossRefPubMed

Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators (2005) Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 353(26):2769–2778. https://doi.org/10.1056/NEJMoa050460CrossRefPubMed

Inati A, Khoriaty E, Mussalam KM (2011) Iron sickle-cell disease: what have we learned over the years? Pediatr Blood Cancer 56(2):182–190. https://doi.org/10.1002/pbc.22721CrossRefPubMed

10.

Thuret I (2013) Post-transfusional iron overload in the haemoglobinopathies. C R Biol 336(3):164–172. https://doi.org/10.1016/j.crvi.2012.09.010CrossRefPubMed

11.

Cohen A, Masera G, Zoumbos N, Uysal Z, Boulet D, Watman N et al (2005) Effect of iron intake on control of body iron in patients with Thalassemia major treated with Deferasirox (Exjade®, ICL670). Blood 106(11):822. https://doi.org/10.1182/blood.V106.11.822.822CrossRef

12.

Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Capellini MD et al (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80(2):168–176. https://doi.org/10.1111/j.1600-0609.2007.00985.xCrossRefPubMedPubMedCentral

13.

Hoffbrand AV, Taher A, Cappellini MD (2012) How I treat transfusional iron overload. Blood 120(18):3657–3669. https://doi.org/10.1182/blood-2012-05-370098CrossRefPubMed

14.

Ward R (2010) An update on disordered iron metabolism and iron overload. Hematology 15(5):311–317. https://doi.org/10.1179/102453310X12647083621164CrossRefPubMed

15.

Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta Mol Cell Res 1823(9):1434–1443. https://doi.org/10.1016/j.bbamcr.2012.01.014CrossRef

16.

Muckenthaler MU, Rivella S, Hentze MW, Galy B (2017) A Red Carpet for Iron Metabolism. Cell 168(3):344–361. https://doi.org/10.1016/j.cell.2016.12.034CrossRefPubMedPubMedCentral

17.

Ganz T, Nemeth E (2006) Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290(2):G199–203. https://doi.org/10.1152/ajpgi.00412.2005CrossRefPubMed

18.

Lynch S, Pfeiffer CM, Georgieff MK, Brittenham G, Fairweather-Tait S, Hurrell RF, McArdle HJ, Raiten DJ (2018) Biomarkers of Nutrition for Development (BOND)-Iron review. J Nutr 148(suppl1):1001S–1067S. https://doi.org/10.1093/jn/nxx036CrossRefPubMedPubMedCentral

19.

Nemeth E (2008) Iron regulation and erythropoiesis. Curr Opin Hematol 15(3):169–175. https://doi.org/10.1097/MOH.0b013e3282f73335CrossRefPubMed

20.

Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101(7):2461–2463. https://doi.org/10.1182/blood-2002-10-3235CrossRefPubMed

21.

Camaschella C, Nai A, Silvestri L (2020) Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 105(2):260–272. https://doi.org/10.3324/haematol.2019.232124CrossRefPubMedPubMedCentral

22.

Omena J, Cople-Rodrigues CS, Cardoso JDA, Soares AR, Fleury MK, Brito FSB et al (2018) Serum hepcidin concentration in individuals with sickle cell anemia: basis for the dietary recommendation of iron. Nutrients 10(4):498. https://doi.org/10.3390/nu10040498CrossRefPubMedPubMedCentral

23.

Mangaonkar AA, Thawer F, Son J, Ajebo G, Xu H, Barrett NJ et al (2020) Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease. Br J Haematol 189(6):1204–1209. https://doi.org/10.1111/bjh.16498CrossRefPubMedPubMedCentral

24.

Ringelhann B, Konotey-Ahulu F, Dodu SR (1970) Studies on iron metabolism in sickle cell anaemia, sickle cell haemoglobin C disease, and haemoglobin C disease using a large volume liquid scintillation counter. J Clin Pathol 23(2):127–134. https://doi.org/10.1136/jcp.23.2.127CrossRefPubMedPubMedCentral

25.

Borges R, Mancuso A, Camey S, Leotti V, Hirakata V, Azambuja G, Castro S (2021) Power and Sample Size for Health Researchers a tool for calculating sample size and statistical power designed for health researchers. Clin Biomed Res 40(4). https://doi.org/10.22491/2357-9730.109542

26.

Porter J, Garbowski M (2013) Consequences and management of iron overload in sickle cell disease. Hematol Am Soc Hematol Educ Program 2013:447–456. https://doi.org/10.1182/asheducation-2013.1.447CrossRef

27.

Walczyk T, von Blanckenburg F (2002) Natural iron isotope variations in human blood. Science 295(5562):2065–2066. https://doi.org/10.1126/science.1069389CrossRefPubMed

28.

Abrams SA (1999) Using stable isotopes to assess mineral absorption and utilization by children. Am J Clin Nutr 70(6):955–964. https://doi.org/10.1093/ajcn/70.6.955CrossRefPubMed

29.

van den Heuvel EG, Muys T, Pellegrom H, Bruyntjes JP, van Dokkum W, Spanhaak S, Schaafsma G (1998) A new method to measure iron absorption from the enrichment of 57Fe and 58Fe in young erythroid cells. Clin Chem 44(3):649–654CrossRefPubMed

30.

Fidler MC, Davidsson L, Zeder C, Walczyk T, Hurrell RF (2003) Iron absorption from ferrous fumarate in adult women is influenced by ascorbic acid but not by Na2EDTA. Br J Nutr 90(6):1081–1085. https://doi.org/10.1079/bjn2003995CrossRefPubMed

31.

Junqueira-Franco MVM, Dutra de Oliveira JE, Nutti MR, Pereira HS, Carvalho JLV, Abrams SA et al (2018) Iron absorption from beans with different contents of iron, evaluated by stable isotopes. Clin Nutr ESPEN 25:121–125. https://doi.org/10.1016/j.clnesp.2018.03.120CrossRefPubMed

32.

International Atomic Energy Agency (IAEA) (2012) Assessment of iron bioavailability in humans using stable iron isotope techniques. Vienna: International Atomic Energy Agency 77 p. No.: 21

33.

Kastenmayer P, Davidsson L, Galan P, Cherouvrier F, Hercberg S, Hurrell RF (1994) A double stable isotope technique for measuring iron absorption in infants. Br J Nutr 7(3):411–424. https://doi.org/10.1079/bjn19940148CrossRef

34.

Chen Z, Griffin IJ, Plumlee LM, Abrams SA (2005) High resolution inductively coupled plasma mass spectrometry allows rapid assessment of iron absorption in infants and children. J Nutr 135(7):1790–1795. https://doi.org/10.1093/jn/135.7.1790CrossRefPubMed

35.

Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C et al (2000) Hepatic iron concentration and total body iron stores in Thalassemia major. N Engl J Med 343(5):327–331. https://doi.org/10.1056/NEJM200008033430503CrossRefPubMed

36.

St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK et al (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105(2):855–861. https://doi.org/10.1182/blood-2004-01-0177CrossRefPubMed

37.

Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA et al (2009) R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 113(20):4853–4855. https://doi.org/10.1182/blood-2008-12-191643CrossRefPubMedPubMedCentral

38.

Labranche R, Gilbert G, Cerny M, Vu KN, Soulières D, Olivié D et al (2018) Liver iron quantification with MR imaging: a primer for radiologists. Radiographics 38(2):392–412. https://doi.org/10.1148/rg.2018170079CrossRefPubMed

39.

Institute of Medicine (US) Panel on Micronutrients (2001) Dietary reference intakes for. In: Vitamin A, Vitamin K (eds) Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press (US)

40.

Teixeira TV, Da Silva ACF, Rodrigues CDSC, Brito FDSB, Canella DS, Citelli M (2023) Food Consumption of people with Sickle Cell Anemia in a Middle-Income Country. Nutrients15(6):1478. https://doi.org/10.3390/nu15061478

41.

Li H, Kazmi JS, Lee S, Zhang D, Gao X, Maryanovich M et al (2023) Dietary iron restriction protects against vaso-occlusion and organ damage in murine sickle cell disease. Blood 141(2):194–199. https://doi.org/10.1182/blood.2022016218CrossRefPubMed

42.

Sarria B, Dainty JR (2010) Comparison of faecal monitoring and area under the curve techniques to determine iron absorption in humans using stable isotope labelling. J Trace Elem Med Biol 24(3):157–160. https://doi.org/10.1016/j.jtemb.2010.01.010CrossRefPubMed

43.

Sudarev VV, Dolotova SM, Bukhalovich SM, Bazhenov SV, Ryzhykau YL, Uversky VN et al (2023) Ferritin self-assembly, structure, function, and biotechnological applications. Int J Biol Macromol 224:319–343. https://doi.org/10.1016/j.ijbiomac.2022.10.126CrossRefPubMed

44.

Cook JD, Lipschitz DA, Miles LEM, Finch CA (1974) Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 27(7):681–687. https://doi.org/10.1093/ajcn/27.7.681CrossRefPubMed

45.

Lynch SR, Skikne BS, Cook JD (1989) Food iron absorption in idiopathic hemochromatosis. Blood 74(6):2187–2193CrossRefPubMed

46.

Roe MA, Collings R, Dainty JR, Swinkels DW, Fairweather-Tait SJ (2009) Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. Am J Clin Nutr 89(4):1088–1091. https://doi.org/10.3945/ajcn.2008.27297CrossRefPubMed

47.

Zimmermann MB, Troesch B, Biebinger R, Egli I, Zeder C, Hurrell RF (2009) Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am J Clin Nutr 90(5):1280–1287. https://doi.org/10.3945/ajcn.2009.28129CrossRefPubMed

48.

Erlandson ME, Walden B, Stern G, Hilgartner MW, Wehman J, Smith CH (1962) Studies on congenital hemolytic syndromes, IV. Gastrointestinal absorption of iron. Blood 19:359–378CrossRefPubMed

Titel: Iron absorption in adults with sickle cell anemia: a stable-isotope approach
verfasst von: Juliana Omena¹
Flávia Fioruci Bezerra¹
Vanessa Monteiro Voll¹
Bernardo Ferreira Braz
Ricardo Erthal Santelli
Carmen Marino Donangelo
Gustavo Federico Jauregui
Andrea Soares Ribeiro
Cláudia dos Santos Cople Rodrigues
Marta Citelli
Publikationsdatum: 09.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-024-03417-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Iron absorption in adults with sickle cell anemia: a stable-isotope approach

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin